Grifols (NASDAQ:GRFS – Get Rating) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Wednesday. Other equities research analysts have also recently issued research reports about the company. Jefferies Financial Group raised Grifols from a “hold” rating to a “buy” rating in a research […]
Shares of Grifols, S.A. (NASDAQ:GRFS – Get Rating) have been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month […]
Grifols, S.A. (NASDAQ:GRFS – Get Rating) rose 6.5% during trading on Thursday . The stock traded as high as $7.09 and last traded at $7.08. Approximately 219,014 shares were traded during trading, a decline of 78% from the average daily volume of 1,014,273 shares. The stock had previously closed at $6.65. Wall Street Analysts Forecast […]
Shares of Grifols, S.A. (NASDAQ:GRFS – Get Rating) gapped up before the market opened on Friday . The stock had previously closed at $10.38, but opened at $10.73. Grifols shares last traded at $10.73, with a volume of 200 shares. Several research firms have commented on GRFS. Berenberg Bank decreased their price target on shares […]
Zacks Investment Research upgraded shares of Grifols (NASDAQ:GRFS – Get Rating) from a sell rating to a hold rating in a report issued on Friday, Zacks.com reports. According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and […]